Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients
IntroductionThere is robust evidence indicating that the SARS-CoV-2-specific humoral response is associated with protection against severe disease. However, relatively little data exist regarding how the humoral immune response at the time of hospital admission correlates with disease severity in unimmunized patients. Our goal was toidentify variables of the humoral response that could potentially serve as prognostic markers for COVID-19 progressionin unvaccinated SARS-CoV-2 patients.MethodsA prospective cross-sectional study was carried out in a cohort of 160 unimmunized, adult COVID-19 patients from the Hospital Universitario 12Octubre. Participants were classified into four clinical groups based on disease severity: non-survivors with respiratory failure (RF), RF survivors, patients requiring oxygen therapy and those not receiving oxygen therapy. Serum samples were taken on admission and IgM, IgG, IgG subclass antibody titers were determined by ELISA, and neutralizing antibody titersusing a surrogate neutralization assay. The differences in the antibody titers between groups and the association between the clinical and analytical characteristics of the patients and the antibody titers were analyzed.ResultsPatients that developed RF and survived had IgM titers that were 2-fold higher than non-survivors (p = 0.001), higher levels of total IgG than those who developed RF and succumbed to infection (p< 0.001), and than patients who required oxygen therapy (p< 0.05), and had 5-fold higher IgG1 titers than RF non-survivors (p< 0.001) and those who needed oxygen therapy (p< 0.001), and 2-fold higher than patients that did not require oxygen therapy during admission (p< 0.05). In contrast, RF non-survivorshad the lowest neutralizing antibodylevels, which were significantly lower compared those with RF that survived (p = 0.03). A positive correlation was found between IgM, total IgG, IgG1 and IgG3 titers and neutralizing antibody titers in the total cohort (p ≤ 0.0036).ConclusionsWe demonstrate that patients with RF that survived infection had significantly higher IgM, IgG, IgG1 and neutralizing titers compared to patients with RF that succumb to infection, suggesting that using humoral response variables could be used as a prognostic marker for guiding the clinical management of unimmunized patients admitted to the hospital for SARS-CoV-2 infection..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in Immunology - 13(2022) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ana Tajuelo [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
COVID disease severity |
|---|
| doi: |
10.3389/fimmu.2022.878812 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ04356724X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ04356724X | ||
| 003 | DE-627 | ||
| 005 | 20230308072815.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2022.878812 |2 doi | |
| 035 | |a (DE-627)DOAJ04356724X | ||
| 035 | |a (DE-599)DOAJb4087925e1b642eeaf7b25d54a142a5f | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC581-607 | |
| 100 | 0 | |a Ana Tajuelo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a IntroductionThere is robust evidence indicating that the SARS-CoV-2-specific humoral response is associated with protection against severe disease. However, relatively little data exist regarding how the humoral immune response at the time of hospital admission correlates with disease severity in unimmunized patients. Our goal was toidentify variables of the humoral response that could potentially serve as prognostic markers for COVID-19 progressionin unvaccinated SARS-CoV-2 patients.MethodsA prospective cross-sectional study was carried out in a cohort of 160 unimmunized, adult COVID-19 patients from the Hospital Universitario 12Octubre. Participants were classified into four clinical groups based on disease severity: non-survivors with respiratory failure (RF), RF survivors, patients requiring oxygen therapy and those not receiving oxygen therapy. Serum samples were taken on admission and IgM, IgG, IgG subclass antibody titers were determined by ELISA, and neutralizing antibody titersusing a surrogate neutralization assay. The differences in the antibody titers between groups and the association between the clinical and analytical characteristics of the patients and the antibody titers were analyzed.ResultsPatients that developed RF and survived had IgM titers that were 2-fold higher than non-survivors (p = 0.001), higher levels of total IgG than those who developed RF and succumbed to infection (p< 0.001), and than patients who required oxygen therapy (p< 0.05), and had 5-fold higher IgG1 titers than RF non-survivors (p< 0.001) and those who needed oxygen therapy (p< 0.001), and 2-fold higher than patients that did not require oxygen therapy during admission (p< 0.05). In contrast, RF non-survivorshad the lowest neutralizing antibodylevels, which were significantly lower compared those with RF that survived (p = 0.03). A positive correlation was found between IgM, total IgG, IgG1 and IgG3 titers and neutralizing antibody titers in the total cohort (p ≤ 0.0036).ConclusionsWe demonstrate that patients with RF that survived infection had significantly higher IgM, IgG, IgG1 and neutralizing titers compared to patients with RF that succumb to infection, suggesting that using humoral response variables could be used as a prognostic marker for guiding the clinical management of unimmunized patients admitted to the hospital for SARS-CoV-2 infection. | ||
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a COVID disease severity | |
| 650 | 4 | |a humoral response | |
| 650 | 4 | |a IgG | |
| 650 | 4 | |a IgM 2 | |
| 653 | 0 | |a Immunologic diseases. Allergy | |
| 700 | 0 | |a Octavio Carretero |e verfasserin |4 aut | |
| 700 | 0 | |a Estéfani García-Ríos |e verfasserin |4 aut | |
| 700 | 0 | |a Estéfani García-Ríos |e verfasserin |4 aut | |
| 700 | 0 | |a Mireia López-Siles |e verfasserin |4 aut | |
| 700 | 0 | |a Olga Cano |e verfasserin |4 aut | |
| 700 | 0 | |a Mónica Vázquez |e verfasserin |4 aut | |
| 700 | 0 | |a Vicente Más |e verfasserin |4 aut | |
| 700 | 0 | |a Isabel Rodríguez-Goncer |e verfasserin |4 aut | |
| 700 | 0 | |a Antonio Lalueza |e verfasserin |4 aut | |
| 700 | 0 | |a Antonio Lalueza |e verfasserin |4 aut | |
| 700 | 0 | |a Francisco López-Medrano |e verfasserin |4 aut | |
| 700 | 0 | |a Francisco López-Medrano |e verfasserin |4 aut | |
| 700 | 0 | |a Francisco López-Medrano |e verfasserin |4 aut | |
| 700 | 0 | |a Rafael San Juan |e verfasserin |4 aut | |
| 700 | 0 | |a Rafael San Juan |e verfasserin |4 aut | |
| 700 | 0 | |a Rafael San Juan |e verfasserin |4 aut | |
| 700 | 0 | |a Mario Fernández-Ruiz |e verfasserin |4 aut | |
| 700 | 0 | |a Mario Fernández-Ruiz |e verfasserin |4 aut | |
| 700 | 0 | |a Mario Fernández-Ruiz |e verfasserin |4 aut | |
| 700 | 0 | |a José Mᵃ Aguado |e verfasserin |4 aut | |
| 700 | 0 | |a José Mᵃ Aguado |e verfasserin |4 aut | |
| 700 | 0 | |a José Mᵃ Aguado |e verfasserin |4 aut | |
| 700 | 0 | |a Michael J. McConnell |e verfasserin |4 aut | |
| 700 | 0 | |a Pilar Pérez-Romero |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Immunology |d Frontiers Media S.A., 2011 |g 13(2022) |w (DE-627)DOAJ000031690 |x 16643224 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fimmu.2022.878812 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/b4087925e1b642eeaf7b25d54a142a5f |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fimmu.2022.878812/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1664-3224 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 | ||